Drug Type Biosimilar, Monoclonal antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism C5 inhibitors(Complement C5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemoglobinuria, Paroxysmal | Preclinical | Singapore | 14 Apr 2022 | |
Hemolytic-Uremic Syndrome | Preclinical | Singapore | 14 Apr 2022 |